Oncolytics Biotech Inc. Announces Director Election Results from its Annual and Special Meeting of Shareholders
CALGARY, May 10, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:
ONCY) announced today that all nominees listed in the management
information circular dated April 4, 2013 were elected as directors at
its 2013 Annual and Special Meeting of Shareholders, held on Thursday,
May 9th, 2013. On a vote by ballot, the following nine nominees
proposed by management were elected as Directors of Oncolytics to serve
until the Company`s next Annual Meeting of Shareholders or until their
successors are elected or appointed, with shares represented at the
meeting voting in favour of individual nominees as follows:
| Director | For | % | Withheld | % |
| Ger van Amersfoort | 21,574,004 | 98.39% | 353,162 | 1.61% |
| Matthew Coffey | 20,068,776 | 91.52% | 1,858,790 | 8.48% |
| Jim Dinning | 11,788,903 | 53.76% | 10,138,663 | 46.24% |
| Ed Levy | 15,873,150 | 72.39% | 6,054,416 | 27.61% |
| Mark Lievonen | 15,883,690 | 72.44% | 6,03,876 | 27.56% |
| Wayne Pisano | 21,580,329 | 98.42% | 364,837 | 1.58% |
| Robert Schultz | 20,852,657 | 95.10% | 1,074,509 | 4.90% |
| Fred Stewart | 20,965,305 | 95.61% | 961,861 | 4.39% |
| Brad Thompson | 21,550,453 | 98.39% | 376,713 | 1.72% |
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2013 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
Help employers find you! Check out all the jobs and post your resume.